March 9, 2025
Headlines

LENZ Therapeutics’ Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

01 mins

LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval.

read more

Join the newsletter

Subscribe to get our latest content by email.

    We respect your privacy. Unsubscribe at any time.
    Built with Kit

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Related News